Skip to main content

Identification of stool miR-135b-5p as a non-invasive diaognostic biomarker in later tumor stage of colorectal cancer.

Li L, Wang A, Cai M, Tong M, Chen F, Huang L

Publication: Life Sci (2020) • Vol 260 • Page 118417PMID: 32931801View on PubMed

Purpose

This paper compared microRNA (miRNA, miR)-135b-5p levels in serum and fecal specimens from colorectal cancer (CRC) patients and healthy volunteers. Differences in miR-135b-5p levels based on tumor stage were also investigated.

Conclusion

Levels of miR-135b-5p were comparable in serum and fecal specimens from stage-I CRC patients and healthy patients, but significantly higher in specimens from stage-II, stage-III, and stage-IV CRC patients than healthy patients. Receiver operating and characteristic (ROC) curve analysis showed that miR-135b-5p levels in serum and feces effectively distinguished CRC patients from healthy patients and there was no significant difference between the area under curve (AUC) of serum and feces, indicating comparable diagnostic utility.

Studies (1)

Purpose

This study compared miR-135b-5p expression levels in serum and fecal specimens from colorectal cancer patients and healthy volunteers. Differences in miR-135b-5p levels based on tumor stage were also investigated. Serum and fecal specimens were collected from 77 colorectal cancer patients (11 stage-I, 9 stage-II, 23 stage-III, and 34 stage-IV) and 29 healthy controls (no collection or processing details provided). RNA was extracted from fecal specimens using Stool Total RNA Purification Kit Dx and quantified by spectrophotometry. Details for serum processing were not provided. Levels of miR-135b-5p were measured by real-time qRT-PCR.

Summary of Findings

Levels of miR-135b-5p were comparable in serum and fecal specimens from stage-I CRC patients and healthy volunteers, but were 3.12, 6.53, and 7.42-fold higher in serum specimens from stage-II, stage-III, and stage-IV CRC patients than healthy volunteers, respectively, and 4.39, 9.19, and 13.5-fold higher in fecal specimens, respectively (P<0.05, all). ROC curve analysis showed that miR-135b-5p levels in serum and feces effectively distinguished CRC patients from healthy volunteers with a specificity of 72.7% and 74.1%, respectively, and sensitivity of 93.1% and 96.5%; respectively. There was no significant difference between the area under curve (AUC) of serum and feces (0.83 and 0.87, P=0.2559), indicating comparable diagnostic utility.

  • Biospecimens

    FluidFeces
    FluidSerum
  • Preservation Types

    None (Fresh)
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    RNASpectrophotometry
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionBiospecimen location
    Feces
    Serum
    Real-time qRT-PCR SpecificTargeted nucleic acid
    miR-135b-5p